Background: Rotaviruses are the cause of acute gastroenteritis and severe diarrheal diseases in children worldwide. Children under the age of five are more susceptible to rotavirus infections. Due to such as the lack of effective drugs and supportive therapy only, the development of new antiviral agents against rotaviruses is required. Multi-drug-resistant Acinetobacter baumannii is also one of the most challenging Gram-negative bacteria to control and treat due to its antibiotic resistance, particularly in intensive care units.
Objective: This study aimed to investigate the activity of zinc oxide nanoparticles against human rotavirus and multi-drug resistant Acinetobacter baumannii.
Methods: The standard 50% tissue culture infectious dose method and the real-time polymerase chain reaction assay were used to investigate the effects of zinc oxide nanoparticles on rotaviruses. The well diffusion and the minimum inhibitory concentration method were used to assess the antibacterial activity of zinc oxide nanoparticles against Acinetobacter baumannii.
Results: 300 μg/ml of zinc oxide nanoparticles demonstrated the highest anti-rotavirus effects, resulting in a 3.16 logarithmic decrease in virus infectious titer, and a four-unit increase in the cycle threshold value of the real-time polymerase chain reaction assay compared to the untreated control (P value <0.001 and P value = 0.005, respectively). The diameter of the inhibition zone of zinc oxide nanoparticles solution against Acinetobacter baumannii was 17 mm. The minimum inhibitory concentration results of the zinc oxide nanoparticles solution against Acinetobacter baumannii was 1.56 mg/ml.
Conclusion: Our findings showed that zinc oxide nanoparticles could be considered a promising antimicrobial compound.
[http://dx.doi.org/10.1093/jac/dkt316] [PMID: 23934770]
[http://dx.doi.org/10.1186/s12887-018-1291-8] [PMID: 30309343]
[http://dx.doi.org/10.1016/j.ijantimicag.2016.11.011] [PMID: 28089172]
[http://dx.doi.org/10.1016/j.colsurfb.2021.111724] [PMID: 33838582]
[http://dx.doi.org/10.1016/j.vaccine.2020.10.084] [PMID: 33168345]
[http://dx.doi.org/10.1166/jbn.2020.2916] [PMID: 32970978]
[http://dx.doi.org/10.1111/j.1750-3841.2008.01013.x] [PMID: 19200107]
[http://dx.doi.org/10.1016/j.archoralbio.2016.09.003] [PMID: 27653145]
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.089] [PMID: 23953781]